Alnylam Pharmaceuticals, Inc.
ALNY
$438.93
$3.830.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.46B | 2.35B | 2.25B | 2.09B | 2.34B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.46B | 2.35B | 2.25B | 2.09B | 2.34B |
| Cost of Revenue | 402.72M | 328.44M | 323.37M | 306.41M | 304.82M |
| Gross Profit | 2.06B | 2.02B | 1.92B | 1.79B | 2.04B |
| SG&A Expenses | 1.08B | 1.00B | 975.53M | 878.31M | 856.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.64B | 2.46B | 2.43B | 2.28B | 2.24B |
| Operating Income | -180.19M | -115.37M | -176.89M | -188.13M | 102.64M |
| Income Before Tax | -379.58M | -355.38M | -377.38M | -321.10M | -61.70M |
| Income Tax Expenses | -60.49M | -85.68M | -99.22M | 11.16M | 11.24M |
| Earnings from Continuing Operations | -319.09 | -269.70 | -278.16 | -332.26 | -72.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -319.09M | -269.70M | -278.16M | -332.26M | -72.94M |
| EBIT | -180.19M | -115.37M | -176.89M | -188.13M | 102.64M |
| EBITDA | -123.69M | -57.82M | -120.22M | -132.15M | 157.97M |
| EPS Basic | -2.47 | -2.09 | -2.17 | -2.62 | -0.57 |
| Normalized Basic EPS | -1.82 | -1.70 | -1.82 | -1.57 | -0.22 |
| EPS Diluted | -2.47 | -2.10 | -2.17 | -2.62 | -0.60 |
| Normalized Diluted EPS | -1.82 | -1.70 | -1.82 | -1.57 | -0.26 |
| Average Basic Shares Outstanding | 518.01M | 514.12M | 510.58M | 507.07M | 503.70M |
| Average Diluted Shares Outstanding | 518.01M | 514.12M | 510.58M | 507.07M | 509.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |